"Anti-Arrhythmia Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
| Descriptor ID |
D000889
|
| MeSH Number(s) |
D27.505.954.411.097
|
| Concept/Terms |
Anti-Arrhythmia Agents- Anti-Arrhythmia Agents
- Agents, Anti-Arrhythmia
- Anti Arrhythmia Agents
- Antiarrhythmic Drugs
- Drugs, Antiarrhythmic
- Antiarrhythmia Agents
- Agents, Antiarrhythmia
- Antiarrhythmia Drugs
- Drugs, Antiarrhythmia
- Anti-Arrhythmia Drugs
- Anti Arrhythmia Drugs
- Drugs, Anti-Arrhythmia
- Anti-Arrhythmics
- Anti Arrhythmics
Cardiac Depressants- Cardiac Depressants
- Depressants, Cardiac
- Myocardial Depressants
- Depressants, Myocardial
|
Below are MeSH descriptors whose meaning is more general than "Anti-Arrhythmia Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Arrhythmia Agents".
This graph shows the total number of publications written about "Anti-Arrhythmia Agents" by people in this website by year, and whether "Anti-Arrhythmia Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1996 | 4 | 3 | 7 |
| 1997 | 4 | 2 | 6 |
| 1998 | 1 | 0 | 1 |
| 1999 | 4 | 0 | 4 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 5 | 6 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 2 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 3 | 4 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Arrhythmia Agents" by people in Profiles.
-
Advancements in management of ventricular arrhythmias. J Interv Card Electrophysiol. 2023 01; 66(1):1-3.
-
A systematic review and meta-analysis comparing radiofrequency catheter ablation with medical therapy for ventricular tachycardia in patients with ischemic and non-ischemic cardiomyopathies. J Interv Card Electrophysiol. 2023 Jan; 66(1):161-175.
-
Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation. J Am Heart Assoc. 2022 02; 11(3):e020506.
-
Intravenous sotalol-A shortcut to success? J Cardiovasc Electrophysiol. 2022 03; 33(3):343-344.
-
Implementation of a Procainamide-Based Cardioversion Strategy for the Management of Recent-Onset Atrial Fibrillation. Adv Emerg Nurs J. 2021 Jul-Sep 01; 43(3):186-193.
-
Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines-Atrial Fibrillation Registry. Circ Arrhythm Electrophysiol. 2021 02; 14(2):e008961.
-
Amiodarone Use Prior to Cardiac Transplant Impacts Early Post-Transplant Survival. Cardiovasc Drugs Ther. 2021 02; 35(1):33-40.
-
Recruitment, retention, and adherence in a clinical trial: The Pediatric Heart Network's Marfan Trial experience. Clin Trials. 2020 12; 17(6):684-695.
-
Emergency Department Management of Recent-Onset Atrial Fibrillation. Adv Emerg Nurs J. 2020 Jul/Sep; 42(3):176-185.
-
Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Am J Med. 2020 10; 133(10):1187-1194.